Tag Archives: oncology

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) ran up to just short of $10 a share back at the end of March, but since corrected to settle in and around the late $5 mark. This week, however, we’re seeing a bit of upside action, on the announcing...

When we first looked at Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) back in November (post recreational legalization ballots in the US), the company was trading in and around $0.8. By mid to late Feb, this had risen to close to $7 a share...

At the end of March, we asked the question ‘Can Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Continue To Run?’ as part of this piece. We concluded that the spate of catalysts that are set to hit press over the coming six to twelve...

Subsequent to our coverage of Q BioMed Inc (OTCMKTS:QBIO) back on March 23, the company ran up from $4.9 a share to $6.9. It’s since corrected a bit, and currently goes for around $5.3. We outlined our thesis on the stock in March, but...

The biotechnology sector is suffering from a bit of sentiment driven uncertainty right now on the back of the political healthcare environment in the US. Many claim to have a clear picture of what the implications of a Trump driven, and Republican...

Heat Biologics Inc (NASDAQ:HTBX) has been a roller-coaster of a ride over the last six months or so. The company ran up into late 2016 in anticipation of some data from its lead bladder cancer trial, but basically collapsed when the data hit...

OXIS International, Inc. (OTCMKTS:OXIS) just announced that it has entered into a sponsored research agreement with the University of Minnesota, designed to help forward the development of one of its preclinical assets. This is a company we’ve...

Towards the end of last year, we took a look at a small biotech play called Q BioMed Inc (OTCMKTS:QBIO). The company had just logged some gains, and had drawn our attention on the back of this run. At that point, Q BioMed was going for around...

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) ran up towards the end of last week on basically no news, and is running again early session in the US on Monday. March to date, the company is up more than 75%. This company is gaining speculative...

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) has been a real tough stock to hold over the last couple of years. It’s fallen prey to aggressive short sell type manipulation. It’s had clinical halt related development setbacks for...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter